Europe Uterine Cancer Drugs Market – Industry Trends and Forecast to 2030

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Europe Uterine Cancer Drugs Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Published Report
  • Jan 2024
  • Europe
  • 350 Páginas
  • Número de tablas: 211
  • Número de figuras: 43

Europe Uterine Cancer Drugs Market, By Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generics and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) – Industry Trends and Forecast to 2030.

Europe Uterine Cancer Drugs Market

Europe Uterine Cancer Drugs Market Analysis and Insights

The Europe uterine cancer drugs market is a vital segment within the broader oncology pharmaceutical industry, reflecting the increasing prevalence of uterine cancer cases worldwide. Uterine cancer ranks among the most common gynecological malignancies, with an incidence rate that has been steadily rising over the years. Several factors contribute to this trend, including an aging population, the obesity epidemic, and improved diagnostic capabilities, leading to earlier detection. As a result, the market for uterine cancer drugs continues to expand as pharmaceutical companies develop innovative treatments to address the needs of patients facing this challenging disease.

Europe Uterine Cancer Drugs MarketEurope Uterine Cancer Drugs Market

Key drivers of the Europe uterine cancer drugs market include advancements in R&D, a growing emphasis on precision medicine, and an evolving understanding of the molecular mechanisms driving uterine cancer. However, the market faces challenges such as the high cost associated with treatment, lack of skilled personnel, and complex regulatory requirements.

The Europe uterine cancer drugs market is expected to reach USD 1,251,870.80 thousand by 2030 from USD 684,672.98 thousand in 2022, growing at a CAGR of 8.4% during the forecast period of 2023 to 2030.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Thousand

Segments Covered

Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generics and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)

Countries Covered

Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and Rest of Europe

Market Players Covered

Baxter, Eli Lilly and Company, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Viatris Inc., Sanofi, Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals LLC, Merck & Co., Inc., GSK plc., Eisai Co., Ltd., Pfizer Inc. and Getwell Oncology, among others

Market Definition

Uterine cancer drugs comprise a class of pharmaceutical drugs and therapies designed specifically to treat and manage uterine cancer, a malignancy originating in the endometrium, the inner lining of the uterus. These drugs play a critical role in the comprehensive treatment and care of individuals diagnosed with uterine cancer. Their primary objectives are to target, suppress, or eliminate cancerous cells within the uterus, thereby slowing or halting the progression of the disease and reducing associated symptoms, such as abnormal uterine bleeding, pelvic pain, and discomfort.

Europe Uterine Cancer Drugs Market Dynamics

This section deals with understanding the market drivers, restraints, opportunities, and challenges. All of this is discussed in detail below:

Drivers

  • Rising Incidence of Uterine Cancer Worldwide

In recent years, the world has witnessed a notable surge in the prevalence of uterine cancer, emerging as a significant health concern in Europe. The rising incidence of uterine cancer worldwide is a complex and multifaceted issue, influenced by a combination of genetic, lifestyle, environmental, and healthcare factors, which is driving the market growth.

  • Growing Advancements in Targeted Therapy for Uterine Cancer

Advancements in targeted therapy for uterine cancer have been promising in improving treatment outcomes, reducing side effects, and enhancing the quality of life for patients. Targeted therapy is a type of cancer treatment that focuses on specific molecules or pathways involved in the growth and spread of cancer cells rather than broadly affecting rapidly dividing cells, as in traditional chemotherapy.

Targeted therapies are drugs designed to target particular changes in cancer cells. They can be helpful for high risk or advanced uterine cancer.

Thus, growing advancements in targeted therapy for uterine cancer are propelling the market growth.

Europe Uterine Cancer Drugs Market

Opportunity

  • Advancements in Genomic Profiling and Biomarker Discovery

Advancements in genomic profiling and biomarker discovery have had a significant impact on uterine cancer treatment, offering a more targeted and personalized approach to managing the disease. Uterine cancer encompasses a range of subtypes, and these advancements have helped identify genetic variations and molecular characteristics specific to each subtype, allowing for more effective treatment strategies. These advancements have transformed the landscape of uterine cancer treatment and have led to a better understanding of the genetic and molecular characteristics of uterine cancer subtypes, more targeted treatment options, and the potential for earlier detection. As research continues to evolve in this field, it holds promise for further improving patient outcomes and expanding the array of therapeutic options available to individuals with uterine cancer. Thus, advancements in genomic profiling and biomarker discovery are expected to act as an opportunity for market growth.

Challenges/ Restraints

  • High Cost of Uterine Cancer Treatment

The high cost associated with the treatment of uterine cancer treatment is a significant concern in healthcare, impacting both individuals and healthcare systems.

Uterine cancer often requires multimodal treatment, which can include surgery, radiation therapy, chemotherapy, targeted therapy, and hormone therapy. The combined expenses of these various treatment modalities, along with the associated hospital stays, consultations, and follow-up visits, can significantly escalate the overall cost of treatment. Patients with uterine cancer may require hospitalization for surgeries, chemotherapy, or radiation therapy, leading to substantial costs associated with hospital stays, operating room expenses, and inpatient care.

Thus, the high cost of uterine cancer treatment is restraining the market growth.

  • Regulatory Hurdles in the Uterine Cancer Drugs Market

The regulatory hurdles in the uterine cancer drug market are critical factors that shape the development, approval, and accessibility of new treatments. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others are responsible for ensuring the safety, efficacy, and quality of drugs. These agencies set strict standards and guidelines that companies must adhere to during the drug development process.

The regulatory hurdles in the uterine cancer drug market are multifaceted and often prolonged. Thus, it is expected to act as a challenge to market growth.

Recent Developments

  • In October 2023, Merck and Co., Inc. introduced effects from the Phase three KEYNOTE-A39 trial (additionally referred to as EV-302), which turned into collaboration with Seagen and Astellas, comparing KEYTRUDA, Merck’s anti-PD-1 therapy, plus Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, as compared to chemotherapy (gemcitabine plus cisplatin or carboplatin) in sufferers with formerly untreated domestically superior or metastatic urothelial carcinoma. This helped the company to expand the application of their brand KEYTRUDA
  • In October 2023, Eli Lilly and Company announced the acquisition of POINT Biopharma Global, Inc., which has radiopharmaceuticals in its pre-clinical and clinical pipeline used to target multiple types of cancer precisely. This acquisition helped the company to expand oncology capabilities into next-generation radioligand therapies
  • In March 2023, Eisai Co., Ltd. announced the presentation of two abstracts at the Society of Gynaecologic Oncology (SGO) Women's Cancer 2023 Annual Meeting held in person in Tampa, Florida, and at the practice on March 25, 2023. Notable research to be featured in the Scientific Plenary IX: The Best of the Rest session includes a presentation of real-world outcomes and healthcare resource utilization in patients with recurrent or advanced endometrial carcinoma who were rechallenged with platinum chemotherapy in Europe. Also, presented data from the LEAP (LEnvatinib And Pembrolizumab) clinical program, which analyzed tumor response to the arm of lenvatinib (LENVIMA) and pembrolizumab (KEYTRUDA) in the pivotal Phase 3 study 309/KEYNOTE-775 in patients with advanced endometrial carcinoma following at least one previous platinum-based regimen in any setting. This initiative by the company was to raise awareness about LENVIMA treating endometrial cancer
  • In March 2023, Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical USA, Inc. and NATCO Pharma Limited USA subsidiary, announced the launch of the generic version of Revlimid (lenalidomide capsules) in additional strengths of 2.5 mg and 20 mg. The companies launched four additional product strengths in the U.S. market in March 2022. At launch, the companies made all strengths of Lenalidomide available in the U.S. market
  • In December 2022, Sanofi and Innate Pharma SA announced an expansion of their collaboration, with Sanofi licensing a Natural Killer (NK) cell engager program targeting B7H3 from Innate’s ANKETTM (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKETTM targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing, and commercialization. This collaboration helped expand Sanofi’s oncology portfolio in the market

Europe Uterine Cancer Drugs Market Scope

The Europe uterine cancer drugs market is segmented into seven notable segments based on cancer type, treatment type, drug type, age group, route of administration, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Cancer Type

  • Endometrial Cancer
  • Uterine Sarcoma

On the basis of cancer type, the market is segmented into endometrial cancer and uterine sarcoma.

Treatment Type

  • Chemotherapy
  • Immunotherapy
  • Hormone Therapy
  • Targeted Therapy
  • Others

On the basis of treatment type, the market is segmented into chemotherapy, immunotherapy, hormone therapy, targeted therapy, and others.

Drug Type

  • Generics
  • Branded

On the basis of drug type, the market is segmented into generics and branded.

Age Group

  • Geriatric
  • Adults

On the basis of age group, the market is segmented into geriatric and adults.

Route of Administration

  • Parenteral
  • Oral

On the basis of route of administration, the market is segmented into parenteral and oral.

End User

  • Hospitals
  • Cancer Centers
  • Specialty Clinics
  • Others

On the basis of end user, the market is segmented into hospitals, cancer centers, specialty clinics, and others.

Distribution Channel

  • Direct Tender
  • Retail Sales
  • Others

On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others.

Europe Uterine Cancer Drugs Market

Europe Uterine Cancer Drugs Market Regional Analysis/Insights

The Europe uterine cancer drugs market is segmented into seven notable segments based on cancer type, treatment type, drug type, age group, route of administration, end user, and distribution channel.

The countries covered in this market report are Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and Rest of Europe.

Germany is expected to dominate the Europe uterine cancer drugs market due to the strong presence of market players in the region.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Uterine Cancer Drugs Market Share Analysis

The Europe uterine cancer drugs market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.

Some of the major market players operating in the Europe uterine cancer drugs market are Baxter, Eli Lilly and Company, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Viatris Inc., Sanofi, Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals LLC, Merck & Co., Inc., GSK plc., Eisai Co., Ltd., Pfizer Inc., and Getwell Oncology, among others.


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE EUROPE UTERINE CANCER DRUGS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 CANCER TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 EUROPE UTERINE CANCER DRUGS MARKET, REGULATORY FRAMEWORK

5.1 OVERVIEW

5.2 REGULATIONS IN EUROPE

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING INCIDENCE OF UTERINE CANCER WORLDWIDE

6.1.2 GROWING ADVANCEMENTS IN TARGETED THERAPY FOR UTERINE CANCER

6.1.3 RISING AWARENESS OF UTERINE CANCER

6.1.4 RISING COLLABORATIONS AND PARTNERSHIPS AMONG LEADING PLAYERS

6.2 RESTRAINTS

6.2.1 HIGH COST OF UTERINE CANCER TREATMENT

6.2.2 SIDE EFFECTS AND TOXICITY ASSOCIATED WITH CANCER DRUGS

6.3 OPPORTUNITIES

6.3.1 ADVANCEMENTS IN GENOMIC PROFILING AND BIOMARKER DISCOVERY

6.3.2 GROWING R&D ACTIVITIES FOR UTERINE CANCER TREATMENT

6.4 CHALLENGES

6.4.1 REGULATORY HURDLES IN THE UTERINE CANCER DRUGS MARKET

6.4.2 DRUG RESISTANCE IN THE TREATMENT OF UTERINE CANCER

7 EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE

7.1 OVERVIEW

7.2 ENDOMETRIAL CANCER

7.2.1 UTERINE CARCINOSARCOMA

7.2.2 SEROUS ADENOSARCOMA

7.2.3 ADENOSQUAMOUS CARCINOMA

7.2.4 OTHER

7.3 UTERINE SARCOMA

7.3.1 UTERINE LEIOMYOSARCOMA

7.3.2 ENDOMETRIAL STROMAL SARCOMAS

7.3.3 UNDIFFERENTIATED SARCOMA

8 EUROPE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE

8.1 OVERVIEW

8.2 CHEMOTHERAPY

8.2.1 PACLITAXEL

8.2.2 CARBOPLATIN

8.2.3 CISPLATIN

8.2.4 DOXORUBICIN

8.2.5 DOCETAXEL

8.2.6 OTHERS

8.3 IMMUNOTHERAPY

8.4 HORMONE THERAPY

8.4.1 PROGESTINS

8.4.1.1 MEDROXYPROGESTERONE ACETATE

8.4.1.2 OTHERS

8.4.2 AROMATASE INHIBITORS

8.4.2.1 LETRAZOLE

8.4.2.2 ANASTRAZOLE

8.4.2.3 EXEMESTANE

8.4.3 LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS

8.4.3.1 GOSERELIN

8.4.3.2 LEUPROLIDE

8.4.4 OTHERS

8.5 TARGETED THERAPY

8.5.1 LENVATINAB

8.5.2 BEVACIZUMAB

8.5.3 MTOR INHIBITORS

8.5.3.1 EVEROLIMUS

8.5.3.2 TEMSIROLIMUS

8.6 OTHERS

9 EUROPE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE

9.1 OVERVIEW

9.2 GENERICS

9.3 BRANDED

9.3.1 KEYTRUDA

9.3.2 LENVIMA

9.3.3 PROVERA

9.3.4 TEMODAR

9.3.5 JEMPERLI

9.3.6 OTHERS

10 EUROPE UTERINE CANCER DRUGS MARKET, BY AGE GROUP

10.1 OVERVIEW

10.2 GERIATRIC

10.3 ADULTS

11 EUROPE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 PARENTERAL

11.3 ORAL

12 EUROPE UTERINE CANCER DRUGS MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.2.1 PRIVATE

12.2.2 PUBLIC

12.3 CANCER CENTERS

12.4 SPECIALTY CLINICS

12.5 OTHERS

13 EUROPE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 RETAIL SALES

13.3.1 HOSPITAL PHARMACY

13.3.2 RETAIL PHARMACY

13.3.3 ONLINE PHARMACY

13.4 OTHERS

14 EUROPE UTERINE CANCER DRUGS MARKET, BY COUNTRY

14.1 EUROPE

14.1.1 GERMANY

14.1.2 U.K.

14.1.3 FRANCE

14.1.4 RUSSIA

14.1.5 ITALY

14.1.6 SPAIN

14.1.7 TURKEY

14.1.8 BELGIUM

14.1.9 NETHERLANDS

14.1.10 SWITZERLAND

14.1.11 REST OF EUROPE

15 EUROPE UTERINE CANCER DRUGS MARKET, COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: EUROPE

16 SWOT ANALYSIS

17 COMPANY PROFILES

17.1 MERCK & CO., INC.

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 PRODUCT PORTFOLIO

17.1.4 RECENT DEVELOPMENT

17.2 SANOFI

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 PRODUCT PORTFOLIO

17.2.4 RECENT DEVELOPMENT

17.3 EISAI CO., LTD.

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 PRODUCT PORTFOLIO

17.3.4 RECENT DEVELOPMENT

17.3.5 RECENT DEVELOPMENT

17.4 PFIZER INC.

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 PRODUCT PORTFOLIO

17.4.4 RECENT DEVELOPMENT

17.5 TEVA PHARMACEUTICALS USA, INC.

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 PRODUCT PORTFOLIO

17.5.4 RECENT DEVELOPMENT

17.6 AMNEAL PHARMACEUTICALS LLC

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 PRODUCT PORTFOLIO

17.6.4 RECENT DEVELOPMENT

17.7 BAXTER

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENT

17.8 ELI LILLY AND COMPANY

17.8.1 COMPANY SNAPSHOT

17.8.2 REVENUE ANALYSIS

17.8.3 PRODUCT PORTFOLIO

17.8.4 RECENT DEVELOPMENT

17.9 GETWELL ONCOLOGY

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENT

17.1 GSK PLC.

17.10.1 COMPANY SNAPSHOT

17.10.2 REVENUE ANALYSIS

17.10.3 PRODUCT PORTFOLIO

17.10.4 RECENT DEVELOPMENT

17.11 HIKMA PHARMACEUTICALS PLC

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENT

17.12 SUN PHARMACEUTICAL INDUSTRIES LTD.

17.12.1 COMPANY SNAPSHOT

17.12.2 REVENUE ANALYSIS

17.12.3 PRODUCT PORTFOLIO

17.12.4 RECENT DEVELOPMENT

17.13 VIATRIS INC.

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

Lista de Tablas

TABLE 1 EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 2 EUROPE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 3 EUROPE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 4 EUROPE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 5 EUROPE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 6 EUROPE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 7 EUROPE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 8 EUROPE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 9 EUROPE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 10 EUROPE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 11 EUROPE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 12 EUROPE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 13 EUROPE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 14 EUROPE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 15 EUROPE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 16 EUROPE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 17 EUROPE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 18 EUROPE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 19 EUROPE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 20 EUROPE UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 21 GERMANY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 22 GERMANY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 23 GERMANY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 24 GERMANY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 25 GERMANY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 26 GERMANY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 27 GERMANY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 28 GERMANY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 29 GERMANY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 30 GERMANY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 31 GERMANY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 32 GERMANY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 33 GERMANY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 34 GERMANY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 35 GERMANY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 36 GERMANY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 37 GERMANY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 38 GERMANY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 39 GERMANY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 40 U.K. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 41 U.K. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 42 U.K. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 43 U.K. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 44 U.K. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 45 U.K. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 46 U.K. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 47 U.K. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 48 U.K. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 49 U.K. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 50 U.K. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 51 U.K. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 52 U.K. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 53 U.K. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 54 U.K. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 55 U.K. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 56 U.K. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 57 U.K. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 58 U.K. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 59 FRANCE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 60 FRANCE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 61 FRANCE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 62 FRANCE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 63 FRANCE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 64 FRANCE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 65 FRANCE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 66 FRANCE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 67 FRANCE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 68 FRANCE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 69 FRANCE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 70 FRANCE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 71 FRANCE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 72 FRANCE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 73 FRANCE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 74 FRANCE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 75 FRANCE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 76 FRANCE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 77 FRANCE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 78 RUSSIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 79 RUSSIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 80 RUSSIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 81 RUSSIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 82 RUSSIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 83 RUSSIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 84 RUSSIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 85 RUSSIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 86 RUSSIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 87 RUSSIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 88 RUSSIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 89 RUSSIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 90 RUSSIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 91 RUSSIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 92 RUSSIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 93 RUSSIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 94 RUSSIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 95 RUSSIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 96 RUSSIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 97 ITALY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 98 ITALY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 99 ITALY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 100 ITALY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 101 ITALY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 102 ITALY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 103 ITALY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 104 ITALY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 105 ITALY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 106 ITALY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 107 ITALY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 108 ITALY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 109 ITALY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 110 ITALY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 111 ITALY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 112 ITALY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 113 ITALY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 114 ITALY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 115 ITALY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 116 SPAIN UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 117 SPAIN ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 118 SPAIN UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 119 SPAIN UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 120 SPAIN CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 121 SPAIN HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 122 SPAIN PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 123 SPAIN AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 124 SPAIN LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 125 SPAIN TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 126 SPAIN MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 127 SPAIN UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 128 SPAIN BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 129 SPAIN UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 130 SPAIN UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 131 SPAIN UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 132 SPAIN HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 133 SPAIN UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 134 SPAIN RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 135 TURKEY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 136 TURKEY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 137 TURKEY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 138 TURKEY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 139 TURKEY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 140 TURKEY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 141 TURKEY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 142 TURKEY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 143 TURKEY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 144 TURKEY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 145 TURKEY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 146 TURKEY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 147 TURKEY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 148 TURKEY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 149 TURKEY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 150 TURKEY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 151 TURKEY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 152 TURKEY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 153 TURKEY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 154 BELGIUM UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 155 BELGIUM ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 156 BELGIUM UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 157 BELGIUM UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 158 BELGIUM CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 159 BELGIUM HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 160 BELGIUM PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 161 BELGIUM AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 162 BELGIUM LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 163 BELGIUM TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 164 BELGIUM MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 165 BELGIUM UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 166 BELGIUM BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 167 BELGIUM UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 168 BELGIUM UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 169 BELGIUM UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 170 BELGIUM HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 171 BELGIUM UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 172 BELGIUM RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 173 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 174 NETHERLANDS ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 175 NETHERLANDS UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 176 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 177 NETHERLANDS CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 178 NETHERLANDS HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 179 NETHERLANDS PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 180 NETHERLANDS AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 181 NETHERLANDS LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 182 NETHERLANDS TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 183 NETHERLANDS MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 184 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 185 NETHERLANDS BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 186 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 187 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 188 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 189 NETHERLANDS HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 190 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 191 NETHERLANDS RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 192 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

TABLE 193 SWITZERLAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 194 SWITZERLAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 195 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 196 SWITZERLAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 197 SWITZERLAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 198 SWITZERLAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 199 SWITZERLAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 200 SWITZERLAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 201 SWITZERLAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 202 SWITZERLAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 203 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 204 SWITZERLAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)

TABLE 205 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)

TABLE 206 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 207 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 208 SWITZERLAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 209 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 210 SWITZERLAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 211 REST OF EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)

Lista de figuras

FIGURE 1 EUROPE UTERINE CANCER DRUGS MARKET: SEGMENTATION

FIGURE 2 EUROPE UTERINE CANCER DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE UTERINE CANCER DRUGS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE UTERINE CANCER DRUGS MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 EUROPE UTERINE CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE UTERINE CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE UTERINE CANCER DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE UTERINE CANCER DRUGS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 EUROPE UTERINE CANCER DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE UTERINE CANCER DRUGS MARKET: SEGMENTATION

FIGURE 11 RISING INCIDENCE OF UTERINE CANCER IS DRIVING THE GROWTH OF THE EUROPE UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 12 THE ENDOMETRIAL CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 AND 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE UTERINE CANCER DRUGS MARKET

FIGURE 14 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2022

FIGURE 15 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2023-2030 (USD THOUSAND)

FIGURE 16 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, CAGR (2023-2030)

FIGURE 17 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 18 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2022

FIGURE 19 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)

FIGURE 20 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, CAGR (2023-2030)

FIGURE 21 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 22 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2022

FIGURE 23 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)

FIGURE 24 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030)

FIGURE 25 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 26 EUROPE UTERINE CANCER DRUGS MARKET: BY AGE GROUP, 2022

FIGURE 27 EUROPE UTERINE CANCER DRUGS MARKET: BY AGE GROUP, 2023-2030 (USD THOUSAND)

FIGURE 28 EUROPE UTERINE CANCER DRUGS MARKET: BY AGE GROUP, CAGR (2023-2030)

FIGURE 29 EUROPE UTERINE CANCER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 30 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 31 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)

FIGURE 32 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 33 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 34 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, 2022

FIGURE 35 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 36 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 37 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 39 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 40 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 41 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 42 EUROPE UTERINE CANCER DRUGS MARKET: SNAPSHOT (2022)

FIGURE 43 EUROPE UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The Europe Uterine Cancer Drugs Market size will be worth USD 1,251,870.80 thousand by 2030 during the forecast period.
The Europe Uterine Cancer Drugs Market growth rate is 8.4% during the forecast period.
Rising Incidence of Uterine Cancer Worldwide and Growing Advancements in Targeted Therapy for Uterine Cancer are the growth drivers of the Europe Uterine Cancer Drugs Market.
The cancer type, treatment type, drug type, age group, route of administration, end-user, and distribution channel are the factors on which the Europe Uterine Cancer Drugs Market research is based.
Major companies in the Europe Uterine Cancer Drugs Market are Baxter, Eli Lilly and Company, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Viatris Inc., Sanofi, Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals LLC, Merck & Co., Inc., GSK plc., Eisai Co., Ltd., Pfizer Inc., and Getwell Oncology.